Xenon Reports Q3 2024 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Xenon Pharmaceuticals (XENE) PT Raised to $56 at RBC Capital
November 13, 2024 6:48 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $56.00 (from $55.00) while maintaining a Outperform rating.
The analyst comments "All remains on track, heading towards a big 2025 for data, with investigator MDD data 1H25 - which we believe... More
